{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-013196","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.599921+00:00","generated_at":"2026-05-20T03:22:37.055102+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Telomir Pharmaceuticals announces BIO 2025 participation and preclinical progress for Telomir-1","bullets":["Telomir will participate in the BIO International Convention 2025 in Boston from June 16-19, 2025, with scheduled partnering meetings.","The company plans to submit an IND by year-end and initiate first-in-human clinical trials in the first half of 2026.","Preclinical data showed retinal regeneration in AMD, lifespan extension in Progeria/Werner's, reversal of Type 2 diabetes parameters, and ~50% tumor reduction in prostate cancer model.","Telomir launched a rare disease initiative targeting Werner's, Wilson's, Progeria, and dysphonia, and introduced Telomir-Ag2 for multidrug-resistant bacteria including MRSA."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-013196","json":"https://secwatch.observer/filing/0001641172-25-013196.json","markdown":"https://secwatch.observer/filing/0001641172-25-013196.md","text":"https://secwatch.observer/filing/0001641172-25-013196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225013196/0001641172-25-013196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225013196/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-20T03:22:37.055102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}